Kirkland – Pfizer Canada and BioNTech recently filed a New Drug Submission (NDS) with Health Canada for an Omicron-adapted bivalent COVID-19 vaccine candidate, based on the BA.1 sub-lineage, to be administered as a booster dose in individuals 12 years of age and older. This application follows guidance from Health Canada to work towards the introduction of an Omicron-adapted bivalent vaccine …